NEW
YORK, May 1, 2023 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ("Oramed" or the
"Company") (www.oramed.com) announced today the appointment of Mr.
Benjamin Shapiro to its Board of
Directors effective May 1, 2023. The
Board determined that Mr. Shapiro qualifies as an independent
director under the listing rules of the Nasdaq Capital Market.
Ben Shapiro is a successful
entrepreneur and business professional who co-founded The Daily
Wire, a successful, industry leading, international media outlet in
June 2015. Since May 2015, he is host of "The Ben Shapiro Show," a
popular podcast, and he is the author of numerous New York Times best-selling books.
Mr. Shapiro earned a B.A. in Political Science from UCLA in 2004, summa cum laude, and a law degree
from Harvard Law School in 2007, cum
laude.
Mr. Shapiro beneficially owns over four percent of Oramed's
outstanding stock, making him a significant shareholder in the
Company.
The combination of Mr. Shapiro's ownership stake and his real
ability to add value to the Board due to his extensive operational
and business background and acumen makes him a valuable
addition.
"We are excited to welcome Ben onto our Board. Ben's unique
talents and qualifications are expected to bring real value to the
current Oramed Board. We are delighted to begin working in earnest
with him to build shareholder value," said Oramed Chief Executive
Officer, Nadav Kidron.
Mr. Shapiro said, "I believe Oramed is in a unique position to
utilize its current capital effectively in ways that will be
beneficial to its shareholders, given its skilled management and
cash position. I am happy to join Oramed's Board in what I am sure
will be an exciting future for Oramed and its shareholders."
About Oramed Pharmaceuticals
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform
technology pioneer in the field of oral delivery solutions for
drugs currently delivered via injection. The Company's novel
Protein Oral Delivery (POD™) technology is designed to protect drug
integrity and increase absorption. Oramed has offices in
the United States and Israel. For more information, please visit
www.oramed.com.
Forward-looking statements: This press release
contains forward-looking statements. For example, we are using
forward-looking statements when we discuss the benefits to Oramed
and its shareholders from the appointment of Mr. Benjamin Shapiro to its Board of
Directors. These forward-looking statements are based on the
current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements, including the Company's process to
evaluate strategic options; the terms, timing, structure, benefits
and costs of any strategic transaction and whether any transaction
will be consummated at all; the impact of any strategic transaction
on the Company; the outcomes of any litigation, regulatory
proceedings, inquiries or investigations to which the Company may
be subject; the ability to obtain financing or third-party
approvals as needed; our ability to achieve the intended benefits
of our strategic initiatives; the risks and uncertainties related
to the progress, timing, cost, and results of clinical trials and
product development programs; difficulties or delays in obtaining
regulatory approval or patent protection for our product
candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to
conduct our research, development and commercialization activities.
In addition, the following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce
new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
that products may harm recipients; and other factors discussed in
the "Risk Factors" section of the Company's most recent Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q, which are
on file with the Securities and Exchange Commission and in other
filings that the Company makes with the Securities and Exchange
Commission in the future. All of these factors could cause the
actual results or performance of Oramed to differ materially from
those contemplated in such forward-looking statements. Except as
otherwise required by law, Oramed undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.
Company Contact:
Zach Herschfus
+1-844-9-ORAMED
zach@oramed.com
Logo -
https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/oramed-appoints-ben-shapiro-to-its-board-of-directors-301811896.html
SOURCE Oramed Pharmaceuticals Inc.